The 2023 United States Preventive Services Task Force (USPSTF) recommendation for PrEP specifically cites the three medications currently approved by the FDA for use as PrEP. Therefore, it is the position of The Departments, as outlined in FAQ…
Doctors and pharmacists are allowed to compound drugs for individual patients when the compounded drug is not commercially available. Licensed outsourcing facilities (LOF) can compound at a higher volume but can only do so in…
Notable industry trends throughout 2024 include the continued growth of the specialty market. Across the industry, specialty medications now account for an estimated 54% of spending which has been driven mainly by…
Amneal announced FDA approval of exenatide 5mcg/1.2mL and 10mcg/2.4mL prefilled pen injection on November 21, 2024. This generic references Byetta® (exenatide – AstraZeneca), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated…
The Inflation Reduction Act (IRA) of 2022 created the Medicare Drug Price Negotiation (DPN) Program in an effort to decrease the of cost of medications through Medicare. As a result of this program, the Centers for Medicare & Medicaid Services (CMS), select…